Response to RE: Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up
- 146 Downloads
We appreciate the opportunity to address the comments and concerns of van Erning et al. about our study .
As van Erning et al. point out, stage II colon cancer patients are considered for adjuvant chemotherapy mainly in the presence of high-risk prognostic features, such as a T4 lesion, inadequate lymph node sampling, vascular invasion, obstruction or perforation, or a poorly differentiated/undifferentiated histology . These prognostic factors are likely to influence the outcomes such as recurrence and mortality. The primary purpose of our study was to investigate lifestyle changes after diagnosis in relation to quality of life and chemotherapy was used as a surrogate of prognostic features. Thus, detailed information on prognostic factors related to chemotherapy was not recorded during the data collection phase. Although we mentioned that unknown or insufficient information may confound our results, this limitation should be emphasized in the discussion.
KeywordsCancer Survivor American Cancer Society Colon Cancer Patient Enrollment Rate Prognostic Feature
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest. Authors have full control of the primary data and agree to allow the Journal of Supportive Care in Cancer to review if requested.
- 1.Lewis CM, Xun P, He K (2016) Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer 24(4):1656–1661Google Scholar
- 3.Satia JA, Campbell MK, Galanko JA, James A, Carr C, Sandler RS (2004) Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomark Prev 13(6):1022–1031Google Scholar
- 9.Lindskog EB, Gunnarsdóttir KÁ, Derwinger K, Wettergren Y, Glimelius B, Kodeda K (2014) A population-based cohort study on adherence to practice guidelines for adjuvant chemotherapy in colorectal cancer. BMC Cancer 14:948. doi: 10.1186/1471-2407-14-948